Merck

Merck

Yahoo Finance • 15 hours ago

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story

NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Fly on Wall Street News Commentary - Wall Street's major indexes rallied together on Wednesday. As of 2:31 p.m. ET, the Dow Jones Industrial Average was up 1,552.12 points, or 3.0%, at 53,338.84, whil... Full story

Yahoo Finance • 16 hours ago

Bio-Techne (TECH), What Is Behind The Fresh Attention Now?

Bio-Techne (TECH) just put investors on notice with a conditional quarterly dividend of $0.08 per share, tied directly to its pending transaction with Merck KGaA, Darmstadt, Germany, and a key November record date. At a share price of US$... Full story

Yahoo Finance • 20 hours ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Curis Inc. 116,764,683 1.60 1.08 1.195 +0.4811 Helport AI Ltd 105,961,21... Full story

Yahoo Finance • 20 hours ago

Downstream Processing - Global Strategic Business Report 2026: Capitalize on 15.7% CAGR to US$128.9 Billion by 2032 as Danaher, Merck, Sartorius, and Thermo Fisher Reshape Biomanufacturing

Company Logo Boost ROI with automation, single-use systems, continuous processing and real-time analytics that reduce costs, accelerate purification, and improve yield and product quality. Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) -- "Downs... Full story

Yahoo Finance • 21 hours ago

Glycomics / Glycobiology - Global Strategic Business Report 2026: Capitalize on a $4.5 Billion Market by 2032 | Agilent, Bruker, Danaher, Merck, and Thermo Fisher Battle for Share

Company Logo Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) -- "Glycomics / Glycobiology - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global glycomics / glycobiology market was valued at US$1.... Full story

Yahoo Finance • yesterday

State Street Health Care SPDR (XLV) Adds Eli Lilly and J&J on Nov. 2

This article first appeared on GuruFocus. State Street Health Care Select Sector SPDR ETF (XLV) was buying on Monday, with 60 positions increased and none decreased, and no ETFs selling. The fund's ETF activity totaled $175.3 million boug... Full story

Yahoo Finance • 2 days ago

Is Cancer And HIV Trial Wins Altering The Investment Case For Merck (MRK)?

Merck reported fresh Phase 3 wins in oncology and HIV, detailed progress on its personalized mRNA cancer vaccine with Moderna, secured new European approval for KEYTRUDA plus Padcev in bladder cancer, and raised full year 2026 sales guidan... Full story

Yahoo Finance • 2 days ago

Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

ENHANCE-3 study represents Merck's commitment to addressing the burden of COPD exacerbations OHTUVAYRE® is the first and only novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years to combine bronchodilation a... Full story

Yahoo Finance • 2 days ago

Merck to Divest CDMO Business to Lonza

Merck to Divest CDMO Business to Lonza Darmstadt, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Lonza, a global contract development and manufacturing organization, to acquire the CDMO business of Merck Transaction sharpens the focus of Mer... Full story

Yahoo Finance • 3 days ago

BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight

DelveInsight Business Research LLP DelveInsight's report assesses the BTK inhibitors market across the 7MM, with steady growth anticipated through 2036. This growth is driven by the increasing prevalence of B-cell malignancies, the establ... Full story

Yahoo Finance • 3 days ago

Merck Stocks Decline With Higher Target Leaving a New-Launch Scale Test

This article first appeared on GuruFocus. Merck (NYSE:MRK) has a fast-growing medicineand a revenue mix that still demands patience. Shares fell 1.24% to $147.66 at 10:24 a.m. ET on November 2, even as Winrevair's momentum helped lift Can... Full story

Yahoo Finance • 3 days ago

Biotechnology Reagents - Global Strategic Business Report: Capture the US$60.7 Billion Market by 2032 as Thermo Fisher, Roche, Danaher, Merck, and Bio-Rad Drive Disruption

Company Logo R&D investment, CRISPR, NGS, personalized medicine and diagnostics drive demand, while strategic partnerships accelerate reagent innovation and commercialization. Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "Biotechnology Reag... Full story

Yahoo Finance • 3 days ago

Merck (MRK) Pushes Ahead With Oral HIV Regimens And 2027 FDA Review

Merck (NYSE:MRK) outlines new oral HIV treatment and prevention regimens, including once weekly and once monthly dosing schedules. The drugmaker plans to present fresh clinical data from its HIV portfolio at the HIV Glasgow 2026 congress.... Full story

Yahoo Finance • 3 days ago

What Avantis U.S. Equity ETF (AVUS) Bought: Exxon Mobil Leads on Oct. 29

This article first appeared on GuruFocus. Avantis U.S. Equity ETF (AVUS) added to its portfolio last Thursday, with net buying of $213.4 million against $226.2 million in gross ETF activity. The fund increased 434 positions and trimmed 53... Full story

Yahoo Finance • 3 days ago

What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Oct. 29

This article first appeared on GuruFocus. State Street Health Care Select Sector SPDR ETF (XLV) reported $423.4 million in ETF activity last Thursday, all of it buying. The $49.10 billion fund increased all 60 of its positions and decreas... Full story

Yahoo Finance • 3 days ago

ETFs Bought $22.0 Million of Merck (MRK) on Oct. 29

This article first appeared on GuruFocus. ETFs bought $22.0 million of Merck (MRK) on Thursday, with 36 funds adding shares against 20 that sold. ETF activity has favored the stock for four straight sessions, including $19.1 million on We... Full story

Yahoo Finance • 5 days ago

MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds

MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street's expectations in Q3 2026, with sales up 4.7% year on year to $18.0... Full story

Yahoo Finance • 5 days ago

Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks

The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]) closed in the red on Friday, after investors digested corporate results from... Full story

Yahoo Finance • 5 days ago

How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data

Merck and Moderna reported Phase 3 data from the INTerpath-001 trial in resected high-risk melanoma, where personalized mRNA therapy intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 42% and distant metastasis or... Full story

Yahoo Finance • 5 days ago

Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze

Merck came into this Q3 2026 earnings print with the stock already on a steady climb, up about 15% over the past three months. The latest release landed and the market liked what it saw, with the share price gaining 2.2% to close around $1... Full story